Sofosbuvir Patient Input Webinar – Tuesday, October 15


In preparation for our role in steering the Common Drug Review patient input submission for Sofosbuvir, a new HCV direct-acting antiviral, to treat HCV that is moving its way through the next steps of the regulatory approval process, we are hosting a national webinar to share information on the drug from Phase 2 and 3 clinical trials on Tuesday, October 15, 2013 from 2PM-3:30PM (EST). We would like to invite you or a representative from your organization to attend.

CTAC is Canada’s national civil society focusing on access to treatment, and one of our core functions is to generate feedback from people living with HIV, hepatitis C and HIV/HCV co-infection in the form of patient input submissions to the Common Drug Review when a new medication that represents an improvement in the standard of care becomes available in Canada. We are encouraged by the clinical trial results for Sofosbuvir.

If you would like to attend this session, please contact Paul Sutton, Policy Researcher, at [email protected] by Monday, October 14th.